According to EAN/PNS 2021 recommendations for CIDP, anti-MAG-ab should also be tested in all patients fulfilling CIDP diagnostic criteria and in presence of IgM monoclonal gammopathy (90, 94). Here, MAG is linked to monoclonal gammopathy.